Skip to main content

New {seasonal} #influenza {#H3N2} #variant is surging, but #vaccination still our best bet: #WHO (#UN, Dec. 17 '25)

 


16 December 2025 

Amid an early start to the Northern Hemisphere influenza season a new variant of the virus is rapidly gaining ground - but vaccination remains the “most effective defence”, the UN health agency said on Tuesday.


Influenza and other respiratory viruses are surging, Dr Wenqing Zhang, Unit Head for Global Respiratory Threats at the Department of Epidemic and Pandemic Threats Management of the World Health Organization (WHO) told reporters in Geneva, and this year is marked by “the emergence and the rapid expansion of a new AH3N2 virus subclade”.

The new variant - called J.2.4.1 or subclade K - was first noted in August in Australia and New Zealand and has since been detected in over 30 countries, she said.

“Current epidemiological data do not indicate an increase in disease severity, although this genetic shift makes a notable evolution in the virus,” Dr Zhang said.

Influenza viruses are constantly evolving, she explained, which is why the influenza vaccine composition is regularly updated.

“WHO tracks these changes, assesses associated risks to public health and makes vaccine composition recommendations twice a year, through a longstanding global system – the Global Influenza Surveillance and Response System (GISRS), in collaboration with other global experts,” Dr. Zhang said.

The new variant is not part of the composition of the latest vaccines produced for the Northern Hemisphere influenza season, the WHO expert explained.

Still, “early evidence suggests that current seasonal vaccines continue to offer protection against severe diseases and reduce the risk of hospital hospitalization,” she said.

WHO estimates that there are around one billion cases of seasonal influenza annually, including up to five million cases of severe respiratory illness. Up to 650 000 deaths each year are owing to seasonal influenza-related respiratory disease.

“Vaccination remains our most effective defence, including against drifted strains, particularly for high-risk populations and those taking care of them,” Dr Zhang insisted.

The WHO expert shared the results of an early estimation of the vaccine’s effectiveness against the new variant, published in the United Kingdom some weeks ago.

“It's quite promising,” she said, pointing to the data which showed that the vaccine is around 75 per cent effective against severe disease and hospitalization in children and around 35 per cent among adults.

Dr Zhang warned that the upcoming holiday season may bring a further surge in respiratory illnesses. “Advanced planning and preparedness efforts, including encouraging vaccination uptake and strengthening health system readiness, are strongly recommended,” she said.

The WHO expert advised countries to strengthen lab diagnostics and year‑round disease surveillance and to participate in the WHO GISRS surveillance network.

The network comprises influenza centres in 130 countries as well as a dozen reference laboratories.

Asked about whether the United States will remain a member of the network next year despite the country’s decision to leave WHO, effective 22 January 2026, Dr Zhang said that “from the flu perspective, from the respiratory surveillance and preparedness perspective, certainly we would need all the countries in the world to participate in the surveillance, preparedness and a response for influenza and other respiratory viruses because we don't know the next pandemic strain, when and where it would emerge”.

“And that time between the emergence and being picked up and characterized and put into vaccines…it would make a lot of difference with regards to the number of lives that could be saved,” she concluded.

Source: 


Link: https://news.un.org/en/story/2025/12/1166604

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...